Harrow Q4 revenue slightly beats estimates

Harrow

02/03/2026 21:15

Removes bullet point on sales team expansion from the Result Drivers section

Overview

Ophthalmic solutions provider's Q4 revenue rose 33% yr/yr, slightly beating analyst expectations

Adjusted EBITDA for Q4 2025 was $24.2 mln, contributing to $61.9 mln for the year

Company forecasts 2026 revenue of $350 mln to $365 mln and adjusted EBITDA of $80 mln to $100 mln

Outlook

Company forecasts 2026 revenue between $350 mln and $365 mln

Harrow projects 2026 adjusted EBITDA between $80 mln and $100 mln

Result Drivers

PRODUCT DEMAND - Strong demand for VEVYE, IHEEZO, and TRIESENCE drove revenue growth, per CEO Mark L. Baum

OPERATING CASH FLOW - Improved operating cash flow driven by better operating leverage and demand growth

Company press release: ID:nGNX35vd43

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$89.10 mln
$88.45 mln (8 Analysts)
Q4 Gross Margin
79.00%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Harrow Inc is $69.00, about 27.4% above its February 27 closing price of $54.18

The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 32 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)